OncoMatch/Clinical Trials/NCT04562129
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
Is NCT04562129 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including Interleukin-2 and Ipilimumab for melanoma stage iii.
Treatment: Interleukin-2 · Ipilimumab · Nivolumab — The purpose of this study is to find out if the administration of Interleukin-2 concurrently with ipilimumab followed by Nivolumab will result in improved anti-cancer activity and if it is effective for advanced melanoma.
Check if I qualifyExtracted eligibility criteria
Cancer type
Melanoma
Biomarker criteria
Allowed: BRAF V600
Patients with BRAF V600 mutant melanoma must have previously received BRAF targeted therapy for metastatic melanoma and later experienced disease progression. Patients who refuse or decline to receive BRAF targeted therapy or were intolerant of BRAF targeted therapy are eligible.
Disease stage
Required: Stage III, IV
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy (nivolumab, pembrolizumab)
Must have previously received anti-PD1 immunotherapy (nivolumab or pembrolizumab) and later experienced disease progression.
Cannot have received: systemic therapy
Must not have received systemic therapy or radiotherapy (including SRS) within the preceding 3 weeks.
Cannot have received: radiotherapy
Must not have received systemic therapy or radiotherapy (including SRS) within the preceding 3 weeks.
Lab requirements
Blood counts
Must have normal organ and marrow function as specified per protocol.
Kidney function
Must have normal organ and marrow function as specified per protocol.
Liver function
Must have normal organ and marrow function as specified per protocol.
Cardiac function
No evidence of congestive heart failure, symptoms of coronary artery disease, myocardial infarction less than 6 months prior to entry, serious cardiac arrhythmias, or unstable angina. Patients over 40 years old or with cardiac history require a negative or low probability cardiac stress test for ischemia within 8 weeks prior to registration.
Must have normal organ and marrow function as specified per protocol. No evidence of congestive heart failure, symptoms of coronary artery disease, myocardial infarction less than 6 months prior to entry, serious cardiac arrhythmias, or unstable angina. ... negative or low probability cardiac stress test ... within 8 weeks prior to registration.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify